10,448 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. purchased a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 10,448 shares of the company’s stock, valued at approximately $1,472,000.

Other hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its position in Protagonist Therapeutics by 13.2% in the 3rd quarter. GAMMA Investing LLC now owns 3,518 shares of the company’s stock worth $496,000 after buying an additional 409 shares during the period. Farther Finance Advisors LLC lifted its holdings in shares of Protagonist Therapeutics by 442.5% during the third quarter. Farther Finance Advisors LLC now owns 2,398 shares of the company’s stock worth $338,000 after buying an additional 1,956 shares during the last quarter. Engineers Gate Manager LP bought a new stake in shares of Protagonist Therapeutics in the second quarter valued at approximately $536,000. Arizona State Retirement System boosted its position in shares of Protagonist Therapeutics by 2.5% in the second quarter. Arizona State Retirement System now owns 14,085 shares of the company’s stock valued at $1,727,000 after acquiring an additional 347 shares during the period. Finally, Nykredit A S bought a new stake in shares of Protagonist Therapeutics in the second quarter valued at approximately $296,000. Institutional investors own 98.63% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on PTGX shares. Citigroup upped their target price on shares of Protagonist Therapeutics from $175.00 to $182.00 and gave the company a “buy” rating in a research note on Monday, August 31st. The Goldman Sachs Group upgraded shares of Protagonist Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $110.00 to $186.00 in a report on Monday, August 10th. Barclays lifted their target price on Protagonist Therapeutics from $153.00 to $180.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 1st. Truist Financial boosted their price target on Protagonist Therapeutics from $145.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Finally, Wall Street Zen lowered Protagonist Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $158.19.

Protagonist Therapeutics Stock Performance

Shares of Protagonist Therapeutics stock opened at $140.32 on Tuesday. Protagonist Therapeutics, Inc. has a twelve month low of $74.03 and a twelve month high of $160.81. The firm has a market cap of $9.08 billion, a P/E ratio of 136.23 and a beta of 1.53. The firm’s 50-day simple moving average is $144.21 and its 200-day simple moving average is $114.93.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Wednesday, August 5th. The company reported $2.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.27 by $0.02. The business had revenue of $213.47 million during the quarter, compared to analysts’ expectations of $212.03 million. Protagonist Therapeutics had a return on equity of 12.03% and a net margin of 29.40%. The firm’s revenue was up 3746.8% on a year-over-year basis. On average, equities analysts forecast that Protagonist Therapeutics, Inc. will post 4.59 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 7,278 shares of the business’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $144.10, for a total value of $1,048,759.80. Following the completion of the transaction, the chief executive officer directly owned 522,968 shares of the company’s stock, valued at approximately $75,359,688.80. The trade was a 1.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Asif Ali sold 58,629 shares of the business’s stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $141.78, for a total value of $8,312,419.62. Following the sale, the chief financial officer owned 59,003 shares of the company’s stock, valued at approximately $8,365,445.34. The trade was a 49.84% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 283,629 shares of company stock valued at $41,443,786. 5.19% of the stock is currently owned by corporate insiders.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc is a biopharmaceutical company focused on discovering and developing peptide-based medicines for immune-mediated and hematologic diseases. The company uses its proprietary peptide technology platform to design therapies intended to act on specific biological pathways and receptors.

Its leading program is icotrokinra, also known as JNJ-2113, an oral, targeted inhibitor of the interleukin-23 receptor being developed in collaboration with Janssen Pharmaceuticals for inflammatory and immune-mediated conditions, including psoriasis and inflammatory bowel diseases.